About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGNA

Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

A Phase I, Prospective, Single-Arm Feasibility Study: Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response (EASY)

NCT06831032•University Health Network, Toronto

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Prostate AdenocarcinomaIliac Nodal DiseasePara-aortic Lymph Node Metastasis+2 more

Interventions

Adaptive radiotherapy using SBRT

Locations

1

Canada

Locations (1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Key Dates

Start Date

July 7, 2026

Primary Completion Date

July 7, 2029

Completion Date

July 7, 2029

Last Updated

March 23, 2026

Related Studies

RECRUITINGPhase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

RECRUITINGPhase 2

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

NCT06173362

Advanced Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8+1 more

RECRUITINGPhase 3

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

NCT06205316

Biochemically Recurrent Prostate CarcinomaOligometastatic Prostate Carcinoma+5 more

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

NCT06470750

Prostate Adenocarcinoma

RECRUITINGPhase 3

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084

Prostate Adenocarcinoma

RECRUITINGPhase 2

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152

Oligometastatic Prostate CarcinomaProstate Adenocarcinoma+3 more

View all related studies

Contacts

Andrew McPartlin, MD

CONTACT

416-946-4501 andrew.mcpartlin@uhn.ca

Sponsors

Lead Sponsor

University Health Network, Toronto

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 23, 2026Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions